Docetaxel for Advanced Endometrial Cancer
Author Information
Author(s): Katsumata N, Noda K, Nozawa S, Kitagawa R, Nishimura R, Yamaguchi S, Aoki D, Susumu N, Kuramoto H, Jobo T, Ueki K, Ueki M, Kohno I, Fujiwara K, Sohda Y, Eguchi F
Primary Institution: National Cancer Center Hospital, Tokyo, Japan
Hypothesis
Does docetaxel have antitumour activity in patients with advanced or recurrent endometrial carcinoma?
Conclusion
Docetaxel shows antitumour activity in patients with advanced or recurrent endometrial cancer, but the effect is temporary and often accompanied by significant neutropenia.
Supporting Evidence
- Overall response rate was 31%, with complete response in 3% and partial response in 28%.
- 94% of patients experienced grade 3 or 4 neutropenia.
- The median duration of response was 1.8 months.
- The median time to progression was 3.9 months.
- Most patients had undergone prior surgery, with 88% having total abdominal hysterectomy.
Takeaway
This study tested a medicine called docetaxel to see if it helps people with a serious type of cancer. It worked for some, but many had side effects.
Methodology
Patients with advanced or recurrent endometrial cancer received docetaxel 70 mg/m² every three weeks for up to six cycles, with response and toxicity evaluated.
Potential Biases
Potential bias due to the single-arm design and lack of a control group.
Limitations
The study had a relatively small sample size and was limited to a specific patient population.
Participant Demographics
Median age was 59 years, with a range of 39 to 74 years; 42% had received prior chemotherapy.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 16.1–50.0%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website